• Explore how collaboration across manufacturers and the broader healthcare ecosystem is evolving to support expanded access, including readiness for future oral obesity therapies
• Discuss how alternative access models can work in parallel with established pathways to reach more patients and support the next generation of obesity treatments"
Ilya Yuffa, President Lilly USA, Eli Lilly & Company
- How patient, physician, and payer expectations have changed — reshaping the rhythm of healthcare around speed, simplicity, access, and relevance
- Why AI in commercialization has yet to deliver the impact leaders expect — and how some are challenging assumptions, intent, and organizational design to create value faster
- What it takes to design a pharma organization that delivers zero distance to the patient — the decisions, data, and execution needed to meet and beat customer expectations and drive better outcomes
Maria Whitman, Managing Partner, Global Commercialization Strategy and Solutions, ZS
- Accelerate patient access by implementing DTC models that reduce prescription abandonment and compress the journey from diagnosis to active therapy
- Transform patient data assets by creating direct touchpoints that generate continuous insights into behaviors, barriers, and unmet needs traditional channels cannot reveal
Luis Briz, President, Professional Health, Nestle Health Science U.S.
Paul Burton, Chief Medical Officer, Amgen
Stuart Blitz, Co-Founder/COO, Hone Health
Sankalp Sethi, Principal, Patient Services and Direct to Patient, ZS
This interview will be moderated by a Reuters journalist under the Reuters Trust Principles
Ashley Magargee, CEO, Genentech
- Discuss biosimilar pricing trends and uptake patterns, and how market dynamics are changing with recent regulatory shifts toward streamlining biosimilar development
- Examine roadblocks to biosimilar adoption and strategies that can improve patient access to biologic medicines
Thomas Newcomer, Senior Vice President, Head of US Commercial, Samsung Bioepis
- Learn why legacy analytics tools couldn't answer ""What, Why, and How"" fast enough, and how AI agents that perform analysis, not just assist, changed the equation
- See how a semantic foundation lets non-technical field leaders ask complex questions and get instant, governed, auditable answers, no analyst queue
- Take home a concrete business case, without the hype, covering vendor cost reduction, higher HCP engagement, and treatment insights that shaped brand strategy
Ashutosh Katiyar, Executive Director, Commercial Strategy, Insights & Analytics, Regeneron
Chris Walker, Head of Product Marketing, Tellius
- Assess whether accelerated launch capabilities create a competitive divide between ""first-mover"" and ""follower"" companies that influences market share capture, payer positioning, and long-term brand equity within therapeutic categories
- Dissect operational models from biotech disruptors and digital health companies to understand whether their speed-to-market advantage represents replicable frameworks or requires reconsideration of traditional pharmaceutical commercial infrastructure
- Evaluate how compressed timelines could alter pharmaceutical commercial models beyond immediate efficiency gains, examining implications for portfolio strategy, resource allocation, and sustained competitive advantage in dynamic markets
Mike Petroutsas, President, Head of US, Astellas
Vicky Brown, SVP, US Franchise Head of Oncology and Emerging Areas, Boehringer Ingelheim
Justin Holko, SVP, Head, Global Oncology/Hematology Commercial Business Unit, Regeneron
Osama Hashmi, Dermatologist, CEO & Co-founder, Impiricus
Moderator: Jonathan Elliott, Content Director, Reuters Events
Reuters Editorial Interview: Inside the FTC’s Antitrust Agenda: A Reuters News Conversation with Daniel Guarnera
This interview will be moderated by a Reuters journalist under the Reuters Trust Principles
Daniel Guarnera, Director, Federal Trade Commission Bureau of Competition
Moderator: Jody Godoy, Reuters Antitrust Correspondent
- Gain competitive advantage by discovering how leading pharma organizations are strategically reallocating resources and redefining commercial roles to thrive in the AI era
- Accelerate your ROI with practical frameworks and investment insights that help you prioritize AI capabilities across the entire product lifecycle, from launch to loss of exclusivity
- Future-proof your commercial organization by learning which new skills, technologies, and operational models are essential to staying ahead as AI reshapes pharma commercialization
Craig Ackerman, Partner, Alexander Group
Reuters journalists take the audience inside their reporting on how President Donald Trump is reshaping U.S. health policy in his second term, examining the political strategy, regulatory shifts and industry repercussions behind a rapidly evolving agenda.
Drawing on extensive coverage across the White House, federal agencies and Capitol Hill, the panel explores what the administration’s early moves signal for drug pricing, public health priorities, healthcare regulation and the pharmaceutical industry, and where rhetoric may collide with reality.
Michele Gershberg, Global Health & Pharmaceuticals Editor, Reuters
Trevor Hunnicutt, White House Correspondent, Reuters
Leah Douglas, Health Correspondent (Acting), Reuters
Moderator: Caroline Humer, U.S. Health and Pharmaceuticals Editor, Reuters
- Anticipate early customer needs by leveraging real world data to identify unmet needs to each HCP segment
- Link field activities to outcomes by tracking metrics that demonstrate how scientific conversations translate into clinical action
- Personalize field engagement through content matched to HCP preferences and delivered via optimized digital and in-person touchpoints
Sebastien Michaud, Head of Oncology, North America Medical Affairs, EMD Serono
• Align brand strategy across all channels and unify orchestration to overcome strategy execution challenges and improve business outcomes more efficiently
• Leverage AI to drive efficiencies in HCP intelligence, operationalize speed, and support two-way insight sharing between field and marketing teams
• Build credibility and drive adoption by embedding trust-building behaviors, transparency, and relevance into every recommendation and every stakeholder touchpoint
Stephen Onikoro, Chief Operating Officer, PharmaForceIQ
Peter Finlayson, Vice President, Marketing , Palvella Therapeutics
- Align medical and commercial teams for collaborative value and compliance through co-created engagement plans and transparent communication protocols
- Maximize impact with limited resources by deploying digital-first strategies, creating specialist roles for high-value accounts, and using AI to prioritize efforts
- Secure investment in field excellence by quantifying field contributions with data that demonstrates ROI, competitive advantage, and strategic value to leadership
Florin Dracia, VP, US Medical Affairs, Shionogi Inc
Marie-Ange Noue, Senior Director, Head of Scientific Communications, EMD Serono
Moderator: Marcos Mendell, Partner, Beghou
Precision at scale: Uncover instant insights from integrated data to personalize every HCP and patient touch point
- Accelerate insights generation on impact of new clinical data, market drivers, barriers, and untapped opportunities, with future sensitivity analysis capabilities
- Achieve true omnichannel by orchestrating modular content and NBA across field outreach and point of care
- Enable brand team to unlock hidden growth opportunities to driven brand planning process and transform data intelligence to guide future enhancements
Saket Malhotra, Global Head of Commercial Digital, BioMarin Pharma
- From marketing to field teams: Understand the rationale behind every action and execute with clarity by delivering "why this, why now" recommendations directly through CRM to guide call plans, emails and medical follow-ups to
- Dynamically adjust targeting in minutes rather than months by fusing live engagement data with hyper-local access intelligence
- Validate investment by measuring quantified improvements in engagement, prescriptions and revenue whilst establishing clear governance, change management and time-to-value frameworks that de-risk enterprise adoption
Elizabeth Beringer, President, Real Chemistry Media
- Architecting customer engagement that is unified across all ecosystem partners
- Using AI tools to improve speed of content MLR approval to enable precision customer engagement
- Inform the next engagement opportunity through measurements based on behaviour change rather than pure reach and frequency
Joanna Davison, Sr. Director, Marketing Operations and Platform, GSK
Graham Goodrich, Chief Commercial Officer, Apnimed
Harsh Gandhi, Executive Director, Global Head of Commercial Excellence & Digital Marketing, AstraZeneca
Moderator: Shannon Hartley, Managing Director Consulting Health Science & Wellness, EY
- Synchronize engagement and leverage AI and data to transform content strategy—from modular frameworks to dynamic personalization at scale
- Reach HCPs where prescribing decisions happen by embedding prompts within trusted in-workflow touchpoints, including EHRs and point-of-care media
- Measure commercial impact through relevance-based KPIs, like new starts and adherence, whilst maintaining AI compliance with auditable, role-based controls
Pradeep Mangalath, Senior Director of Strategic Initiatives, AI for Patient Services, Sanofi
Jeff Smith, Head of Field Reimbursement, US, Sanofi
From Patient Demand to Prescriber Action in GLP-1s: How Predictive Approaches Unlock Marketing Alignment
• Identify brand-eligible patients earlier by using predictive signals to spot likely candidates before therapy initiation or switch events.
• Trigger “just-in-time” HCP + DTC communications by aligning outreach to key journey moments (diagnosis, prior auth friction, treatment consideration, initiation, and persistence risk).
• Measure true marketing-driven impact with patient- and provider-level outcomes that connect exposure to actions like office visits, new writers, starts, and persistence—not just clicks and reach.
John Flemming, VP Commercial Insights & Analytics, OptimizeRx
• Engage rare disease patients, caregivers, and HCPs with empathetic communication strategies informed by lived experience
• Strengthen trust and improve outcomes by integrating patient insights across the full drug lifecycle to ensure messaging, resources, and support remain relevant, credible, and aligned with real needs
• Enhance launch performance by combining the power of AI with human understanding to optimize targeting, personalize experiences, and create meaningful connections for rare disease brands
Kim Moran, SVP & Head of U.S. Rare Disease, UCB
James Smith, Director, Marketing ATTR, AstraZeneca
Eric Peacock, Co-founder and President of MyHealthTeam and Swoop Chief Patient Officer
Corey Blair, VP Head of Global Marketing, KalVista Pharmaceuticals
- Convert scripts in the post-visit window by synchronizing rep calls with sequenced follow-ups to compound engagement
- Maximize HCP engagement and preserve impact as in-person access shrinks by directing resources toward high-access offices and embedding NBAs
- Connect the dots across hybrid sales by linking rep actions with EHR, endemic, and point-of-care touchpoints, integrate access platforms
Alex Condoleon, Chief Medical Affairs Officer of Medical Engagements & Impact, Pfizer
• Understand why HCPs and patients are demanding responsive, two-way communication via email and SMS, and why pharma's broadcast-mode approach is falling short of their expectations
• Learn why AI is the critical enabler that makes two-way communication finally possible, addressing the compliance, monitoring, and content barriers that have held pharma back
• Explore practical ways AI-orchestrated conversations across website, email, and SMS can drive measurable lifts in HCP and patient engagement and close the gaps that remain
Andrea Goudie, Head of Strategy and Partnerships, Ostro
- Be intentional on human perspective and lead with non-direct value such as educational materials and unbiased, evidence-based decision support tools
- Deliver institutional value beyond product-focused marketing by deploying coordinated health system campaigns
- Deepen brand loyalty and access on community level by delivering culturally relevant education and streamlined prescription journeys
Karishma Parikh, Head of Marketing, Uro-Oncology, Ferring Pharmaceuticals
Maya Schlessinger, HER2+ Launch Lead, Global Marketing, Pfizer
Sara Rubin, Spherico, SVP Market Access Insights and Strategy Lead, Syneos Health
Eduardo Molina, VP Business Operations, Strategy and Chief of Staff to North America President, Ipsen
- Look beyond vendor marketing to differentiate 'Agentic AI' claims that deliver operational value to those that are simply repackaged automation
- Match AI capabilities to pharma needs by identifying fit-for-purpose solutions that solve specific problems without full agent complexity
- Learn from real-world implementation stories including almost-agent builds, technical obstacles encountered, and AI tools generating proven impact today
Dileep Shankar, Head of Data & AI Engineering, Takeda
- Where AI agents are delivering value now: How commercial teams are improving HCP engagement, reducing cycle times, and scaling compliant execution with agent‑powered workflows.
- A practical blueprint for scaling AI across commercial: A clear path from Copilot in daily workflows → domain‑specific agents → multi‑agent systems orchestrating targeting, content production, omnichannel activation, and payer pull‑through.
- The human + agent model for modern commercial teams: How leaders keep humans in control - providing strategy and judgment - while agents automate repeatable tasks and drive consistent, high‑quality execution.
Eunice Youhanna, Global Commercial Pharma Lead, Microsoft
- Accelerate tech integrations through early frameworks with procurement and compliance decisionmakers
- Prevent costly silos and integration nightmares through governance-first strategies that establish standards and architecture before software purchases
- Meet regulatory requirements, address cultural barriers, and secure sustained adoption that delivers ROI through integrated compliance and early cross-functional leadership
Xingchu Liu, SVP, Head of Data, Digital & Analytics, Genentech
Chuck Sachs, Director, US Commercial Innovation, AstraZeneca
Darshan Joshi, Head of Commercial Data Management and Analytics, DD&T, Takeda
Nadia Tantsyura, Executive Director, Worldwide Omnichannel Excellence Insights & Measurement, Bristol Myers Squibb
Moderator: J. Cris Salinas, Head of Industry Strategy, Healthcare and Life Sciences, Adobe
- Establish enterprise-wide capability with AI and predictive analytics to deliver value by creating unified data layers that eliminate fragmentation across systems
- Enable trusted decision-making by deploying governance frameworks with defined ownership, quality standards, and compliance controls that maintain data integrity
- Bridge structured and unstructured data sources through integration platforms that drive actionable insights across commercial, medical, and access silos
Manu Garg, Senior Director, Global Decision Sciences & Insights (GDSI) – HIV PrEP, Gilead Sciences
Vaishali Chaudhuri, Director Marketing Sciences, Gilead Sciences
- Assess the shift from discrete AI agents to embedded, ambient intelligence in core commercial systems, including implications for scale, governance, and user adoption
- Understand why human-in-the-loop and event-driven triggers are critical in making AI actionable, trusted, and seamlessly integrated into commercial operations
- Highlight how new development paradigms enable commercial organizations to design and deploy AI agents internally, unlocking speed and business-led innovation
Koto Ueda, Head of US Operations, GenerativeX
- Challenge the algorithm and spot biases, validate assumptions, and drive confident strategic decisions by understanding how analytics engines interpret data
- Filter misled correlations and build strategies on reliable, verifiable evidence by evaluating data quality, source limitations and false insights
- Transform vendor partnerships by asking probing questions that reveal true data differentiation and assess AI's potential to inform market decisions where awareness and evidence are scarce
Alexander Vandevere, Head of Global Commercialization, Immunology, Viatris
Justine Rochon, Head of R&D Data and Quantitative Sciences, SVP, Takeda
Vijay Iyengar, Executive Director, Global Digital Business Transformation, Eisai
Moderator: Chaitanya Badwe, AVP, Advanced Analytics & Insights, Definitive Healthcare
• Align data governance with strategic business initiatives to assist new product launches, enable trusted KPIs, support patient outcomes, and power priority use-cases across therapeutics areas
• Deploy AI enabled governance and quality frameworks to automate data observability, interoperability, accessibility, literacy, integrity, compliance, auditability, and enterprise oversight
• Enable AI use-cases and increase data trust through agentic AI to leapfrog in future state with enriched semantic layer, enterprise ontology, business metadata, and measurable trust index
Kashif Zafar, Enterprise Data Owner (EDO)/Director, Data Governance, Insights & Decision Sciences, Novartis
Sonia Depresco, Executive Director, Emerging Data Products, Novartis
- Why isolated AI successes haven’t translated to enterprise-level value, and how leaders can gain advantage in the era of agentic AI by focusing their transformation efforts on high-leverage decisions that drive the most important outcomes
- What it takes to build an intelligent enterprise: An approach to design AI-native decision flywheels, so sensing is continuous, decisioning is model-first, and execution is agent-orchestrated, with humans and AI working in partnership.
- How to lead this transformation with a practical, three-lane operating model that reimagines the future with AI, proves what works and embeds AI at scale deeply into business as usual.
Aaron Mitchell, Managing Partner, Global Insights, Analytics & AI Lead, ZS
- Reframe digital excellence as human-centered AI by establishing enterprise standards for transparency, consent, and ethical use—ensuring AI augments trust, decision-making, and stakeholder engagement.
- Operationalize trust at scale by making AI outcomes explainable, auditable, and measurable—so leaders can confidently deploy AI across clinical, manufacturing, and commercial programs without compromising accountability or regulatory readiness.
- Anchor AI decisions in real-world context by grounding models in an organization’s proprietary systems and data, domain knowledge, and workflow signals—ensuring outputs are relevant, reliable, and aligned with clinical, operational, and regulatory realities.
Robert Allen, Head of Omnichannel Strategy & Digital Transformation, Global Public Affairs, Gilead
Elaine Hamann, Head of CX Experience, R&D and Employee Experience , Sanofi
Michael Sobotka, VP, Data Science – Global Commercial Analytics, Pfizer
Abhishek N. Lingaraju, Director - Healthcare and Life Sciences, Impetus
- Prepare for faster innovation, better governance, and coordinated deployment across your organization by identifying and assessing centralized versus decentralized AI models
- Match AI platforms to pharma-specific needs by priortising regulatory compliance, data security, and measurable performance across R&D and commercial applications
- Compare vendor solutions using performance benchmarks and use case studies that prove scalability, integration readiness, and tangible value in pharma settings
Christopher Chu, Senior Director, Enterprise GenAI Content, Genentech
Sthiti Tripathy, Senior Director, Content Management, Genentech
- Set AI investment goals across functions to define measurable ROI frameworks and set benchmarks of success
- Examine real-world case studies that showcase successful AI implementation from pilot through scale, including integration strategies, change management, and adoption hurdles overcome
- Develop decision-making frameworks and readiness assessments that identify when pilots are production-ready and establish clear pathways for enterprise-wide deployment
Vera Kutsenko, Founder & CEO, Atrix AI
Elnaz Alipour, Senior Director, Medical Analytics Care Gaps and Customer Segmentation Leader, Pfizer
- Automate high‑volume, rules‑based workflows and preserve human expertise for judgment‑heavy, ethical, and relationship‑driven decisions, revisiting allocations as models and regulations evolve
- Align strategic interpretation, stakeholder engagement, and cross-functional leadership to emphasize investment in irreplaceable human capabilities where professionals create lasting value
- Transform team capabilities through upskilling programs that develop hybrid roles like AI orchestrators who can manage automation while strengthening internal value through milestone delivery and collaborative execution
Gaurav Jaggi, Senior Director, Insights & Analytics, Regeneron
Patrick Leyden, Director, Innovation and Emerging Projects, Merck
Tatyana Fedotova, Director, Product, Commercial Data Science & AI, AstraZeneca
Punit Kumar, Executive Director, Commercial Operations, Novartis
Moderator: Jonathan Kaskey, VP, Sales & Marketing, XSUNT
- Lower launch risk and win early share by crafting a crisp brand story and proof points that outperform standard of care and convert clinical value into compelling HCP and patient reasons to act now
- Ensure seamless uptake by thoughtful positioning and competitive analysis, focusing on strengths to arm field and key account teams with objection handling and deal guardrails
- Drive faster starts by standing up field deployment, omnichannel journeys, and medical–commercial choreography pre-launch so access and onboarding become frictionless growth engines
Anindita Sinha, VP, Commercial Operations, Shionogi
- Learn about AI practices that are already helping top organizations drive stand-out launch and commercial performance
- Understand how leading organizations are embedding human‑in‑the‑loop design to build trust and accelerate value
- Get practical, no‑nonsense guidance on what to do, and what to avoid, at any stage of transformation
Indraneel Mukherjee, Life Sciences Partner, Guidehouse
Anchal Joshi, Product Development & Commercialization (PDC) Lead, Nephrology, GPS&C, Biogen
Michael Palumbo, VP, Immunology, Eli Lilly
- Pull evidence-driven insights to identify high-yield targets and channels by fusing claims, RWE, and digital signals so launch excellence and analytics leaders focus resources where adoption is more guaranteed
- Equip field teams with a solid value story, dynamic targeting, and widespread omnichannel strategy so sales and MSLs convert HCP intent to starts quickly
- Set a pricing and revenue engine that accelerates uptake by pressure-testing price guardrails, activating smart affordability, and using real-time policy and pull-through analytics to pivot plays without disrupting net revenue
Erica Smith, VP, Value & Market Access, Chiesi
Dicla Veliz Salce, IO Women’s Cancer Lead, AstraZeneca
Dilesh Doshi, VP, Global Health Economics and Outcomes Research, Acadia Pharmaceuticals
Moderator: Michele Petruccelli, Partner, Wavestone
- Cut waste and accelerate pull-through of covered prescriptions and patient starts by targeting covered plans and aligning messages to payer economics so resources focus on accounts delivering measurable ROI
- Avoid out-of-pocket surprises, sustain adherence, and guarantee early persistence by equipping teams for 2025/26 Part D redesign and MFN impacts with scripted scenarios
- Reduce payer friction and protect gross-to-net by delivering coding, prior-authorization, and denial-tracking guides and sequencing MSL evidence for rollout
Martin McLaughlin, Chief of Staff and Head of Commercial Excellence, Teva Pharmaceuticals
- Ruthlessly prioritize to achieve deliberate focus on target customers, segments, and messages, resisting over-fragmentation
- Translate launch strategy into an actionable launch roadmap that drives cross-functional alignment and addresses both success enablers and potential barriers
- Enable fast, targeted course correction by maintaining visibility into early execution signals across field behavior, HCP understanding, access, and patient experience
Matt Riordan, Group President, Putnam, Inizio Ignite
Brian Stamm, Consulting Executive and Product Launch Service Lead, Inizio Ignite
- Drive early prescriber momentum by equipping customer engagement teams with real-time intelligence, activating targeted HCP outreach, and deploying brand-eligible patient messaging and collateral at the moment of diagnosis
- Stabilize gross-to-net and forecast accuracy by mapping each policy change to an action play (e.g., rebate change, copay rule update), assigning owners, and measuring impact by account
- Accelerate script growth and maximize launch ROI with by prioritizing sales efforts in markets, equipping reps with geography-specific tactics, and adjusting support resources based on early performance data
Thomas Lampron, Vice President, Oncology Global Marketing, New Products, Merck
Shontelle Dodson, Executive Vice President, Global Head Medical Affairs, Astellas
Rhonda Peebles, Head of US Dermatology, UCB
Moderator: Chris Hayes, Executive Vice President, GM Sales and Strategic Partnerships, Prognos Health
- In the US, GTM models are under more pressure than at any point in the last decade: access is tighter, stakeholders are more fragmented, and expectations are being reset by consumer‑grade experiences in every other part of life
- Redesign how to create, deliver, and adapt value across all stakeholders, including patients, HCPs, payers, health systems, and communities
- Plan earlier and work within each stakeholder group to have sustainable impact with you brand
Shetal Vyas, SVP, Commercial Strategy & Development, Ardelyx, Inc.
- Evolve pre-deal strategy by integrating top-down analog insights with rigorous commercial feasibility assessment to strengthen confidence in pricing, access, and partnership assumptions
- Drive pull-through effectiveness through an iterative model that translates deal expectations into targeted, measurable pull-through objectives aligned with stakeholder behaviors and real-time market signals
- Close the feedback loop with robust post-deal performance evaluation to uncover what worked, what fell short, and what new intelligence can reshape future deal strategy
Chris Binder, Associate Principal, Market Access and Transformative Solutions, CustomerInsights.AI
Jon Knowles, Customer Engagement Director, Market Access and Transformative Solutions, CustomerInsights.AI
- Accelerate decisions and build competitive advantage by converting plan controls into tailored offers, account priorities, and field tools
- Drive script growth and protect share by deploying segmented patient support, training reps on affordability solutions, and activating digital channels to capture at-risk scripts
- Expand market penetration and defend revenue by anticipating competitor moves, prioritizing high-value accounts, and monitoring share performance to reallocate resources quickly
Laurie Ferranda, AVP, Head of Commercial Strategy, Enterprise Strategy, Merck
Harish Nathani, Senior Director, Contract Strategy and Operations, CSL Behring
Abhishek Agrawal, Senior Director, Strategic Initiatives and Market Development, GSK
Dean Erhadt, President & CEO, D2 Solutions
Moderator: Jonathan Elliott, Content Director, Reuters Events
Build the oncology commercial intelligence layer: Turn EHR signals into lifecycle competitive advantages
- Understand how oncology commercial decision-making is constrained by both insight latency and insufficient clinical depth.
- See how oncology-native commercial intelligence and unstructured insights from EHR records across community oncology enables earlier and more precise lifecycle interventions.
- Explore an illustrative roadmap for translating deeper oncology intelligence into earlier and more precise commercial decisions across the product lifecycle
Jonathan Kish, Vice President & Head of Research Sciences, Flatiron Health
- Maximize adoption and margin by pinpointing demand pockets and syncing brand story, field pull-through, and patient activation across priority channels
- Convert evidence into rapid HCP action and durable TRx by turning fresh clinical and RWE signals into compliant claims, rep triggers, and omnichannel refreshes
- Defend and grow revenue by staying ahead of commoditization with early differentiation plays so you time promotions, evolve messaging, and tune contracts only where needed
Elizabeth Arnold, Vice President, Brand Lead, Milvexian, Bristol Myers Squibb
Chris Edmonds, Global Price and Market Access Director, AstraZeneca
Evan Reddick, Senior Director, Medical Head of Leukemia, Takeda
Nataliya Andreychuk, Co-Founder and Chief Executive Officer, Viseven
• Explore how global public affairs and brand teams can design engagement strategies that successfully mobilize headquarters, regional, and local teams to ensure strategic intent translates into consistent, high quality tactical execution.
• Learn methods to deepen patient partnership through evidence generation, effective patient councils, meaningful cocreation, and structured insight loops that enhance daily decision making.
• Understand how to identify and include underrepresented patient populations, improve health literacy, and enhance policy and advocacy engagement to deepen the value of lived experience as a meaningful source of data.
Jacose Bell, Head of Global Public Affairs, Hemophilia, Sanofi
• Understand the opportunity and imperative to support patients more directly than ever as expectations and preferences evolve
• Hear key stats about patient attitudes toward pharma-provided digital health tools and resources to gain insight into what truly resonates
• Unpack tangible ideas for addressing patient concerns and demonstrate commitment to patient-centric innovation
Suzy Jackson, Chief Commercial Officer, Fullspan Health
- Stop asking for permission and start proving value by reframing engagement in the metrics that matter to executives, such as cycle time, submission strength, and cost savings
- Design frameworks for momentum, not bureaucracy by bringing legal and compliance into the process early so engagement can move faster and avoid dying in review
- Build long-term credibility by linking engagement outcomes to strategic business goals, transforming patient partnerships from 'supporting act' to 'performance driver’
Rachel Levine, Executive Director, US Patient Advocacy, Novartis
Elsa LaVita, Senior Director, Patient Advocacy, Cullinan Therapeutics
Monique Mulkern, Head, Global Patient Insights & Solutions (GPIS), Patient Experience Team, Global Medical Affairs, Alexion Pharmaceuticals, Inc
Moderator: Hannah Caldwell, Client Director, Gate One
Design payer grade value from day one: Align evidence, messaging, and pull-through to win access and adoption
- Reduce controls and accelerate coverage by building in comparators, PROs, economics, and site feasibility
- Improve payer turnaround and provider claim quality by orchestrating compliant, insurer ready materials across the pre and post approval phases
- Translate policy risk into targeted, ROI positive deals, and only turn them on where real access exists
Faster, stronger value stories at scale: AI-enabled message & evidence alignment to augment & accelerate launch
- Deliver integrated evidence planning (IEP) through tech enablement that improves efficiency in evidence planning and generation
- Accelerate time from evidence to customer impact through coordinated, quality scientific & value messaging
- Align global strategy and available evidence for greater market impact.
Gavin Outteridge, General Manager, Arysana
Aditi Tuteja, Global Head of Market Access Innovation, Specialty Care, Sanofi
Payer strategy that sticks: Prove value, pre-empt friction, and scale pull-through under rising controls
- Win coverage by prioritizing high-quality RWE, credible comparisons, plan-level budget impact, and delivery proof
- Ensure investment follows confirmed access by scenario-planning price and rebate corridors and sequencing markets
- Speed approvals and pull-through by aligning submissions to reviewer expectations and equipping field and patient support hubs with practical tools
Jason Lott, VP, TA Head of Global Medical & Evidence Cell & Gene Therapy, Ophthalmology, and Women's Healthcare, Bayer
Moderator: Chris Wright, Managing Director, Value and Access, Consulting, Syneos Health
Sanket Shah, Director, Global Value & HEOR, Jazz Pharmaceuticals
Adam Hathorn, Head, National Accounts, US Market Access, Sanofi
• Translate authentic patient narratives into evidence-based plain language messaging to build trust and improve health literacy .
• Curate and prioritize information to combat overload and misinformation to deliver actionable insights to patients to empower informed choices
• Harness advocacy influence and trends to drive equity-focused engagement and improve health outcomes.
• Deliver content across multiple modalities to allow for different learning styles (visual, auditory, kinaesthetic) to enhance comprehension and improve retention
Matthijs van Meerveld, Global Head of Patient Advocacy and Policy, Menarini Stemline
Victoria Goldberg, Patient Advocate
- Build enterprise learning over time by mapping repeated themes from PSPs, registries, and digital touchpoints to influence study design and reimbursement strategy
- Connect adherence, persistence, and quality-of-life data with pre-launch engagement metrics to prove how early insights sustain market performance
- Close the feedback loop through automated pipelines that feed real-world patient sentiment into Medical and Access teams to adjust education and support materials in real time
Sponsored by Avalere Health
- Identify critical touchpoints and tailor messaging for each stage of the patient journey to deliver precision without complexity.
- Embed empathy and build patient trust by integrating digital tools and navigation support into patient programs to create a seamless, human-centered experience
- Build scalable, data-driven frameworks that optimize AI tools to deliver on patient-centricity through connecting the dots across treatment cycles to provide a 360-degree support system
Nicolas Garnier, Chief Patient Officer, Servier
Isabel Silva, Senior Director, Digital Health Solutions - Patient Care, AstraZeneca
Andrea Preuss, Executive Director, Patient Reimbursement Services, Strategy & Operations, Keenova Therapeutics
Phil Johnson, Chief Commercial Officer, Evidation
- Prove Medical Affairs’ value by moving beyond activity metrics to measured scientific exchange aligned to business objectives
- Map medical’s objectives through pre-specified leading and lagging metrics, co-created through cross-stakeholder alliances
- Drive clinical practice change by synthesizing traditional and real-world evidence into actionable insights for HCPs
Divyesh Khetia, VP, Head of Medical Channel Excellence, Pfizer
- Orchestrate omnichannel scientific dialogue through mediums that work to drive efficiency
- Integrate medical communications to target priority HCP segments through providing measurable impact decision matrices
- Translate evidence into action by co-creating narrative arcs rooted in unmet clinical questions and contextualized by localized specialties
- Segment HCPs by clinical questions, data affinities, and channel preferences to update dynamic personas with real-time engagement signals
- Route the right role and asset by matching MSL, Medical Information, or Digital Medical with modular evidence tailored to intent and compliance
- Test, learn, and optimize for outcomes by running message experiments and iteration based on behavior change and decision quality – not reach
David Ginkel, Head of Publications, AstraZeneca
Janine Gaiha-Rohrbach, Head VP, Global Medical Immunology, Biogen
Jeremy Pincus, VP, Medical Affairs Digital and Tech, GSK
Rachel Adams, Head USA Medical Communications and Scientific Training, Takeda
Briana Belford, Practice Leader, Integrated Intelligence, Real Chemistry
- Explore how AI agents can be embedded into document- and spreadsheet-based workflows through live demonstrations of how intelligence becomes part of daily work
- Experience real-time interactions with AI agents in different formats, showing how a single agentic approach can be applied across documents, data, and presentations
- Build and customize simple AI agents during the session, giving participants first-hand experience of rapid AI agent development without conventional engineering efforts
Hiroki Ida, Executive Officer, GenerativeX
- Deliver HCP engagement that more personalized, more measurable, and more complex across channels
- Explore how agentic AI can help teams move from manual orchestration to coordinated execution using intelligent agents to streamline content planning, compliant versioning, channel activation, and performance optimization.
- Gain an understanding of trends and practical scenarios to spark discussion on what’s next with Adobe and Microsoft.
Nonso Anuebunwa, MD, HLS Strategic Advisory, Adobe
Jonas Sjöquist, Life Sciences Strategy Lead, Adobe
Mike Shevlin, Director Northeast Life Sciences & MedTech, Microsoft
Akilah Daniels-Vincent, Sr. Product Marketing Manager, Pharma and MedTech Lead, Microsoft
- Gain a proven framework to prevent stalled pilots and accelerate AI adoption across commercial, patient services, and compliance, moving beyond basic tools to enterprise-scale impact
- Unlock hidden value in your unstructured data by identifying high-ROI opportunities within customer journeys and operationalizing AI through workflow integration and governance
- Make confident AI investment decisions with clear metrics that prove measurable ROI and ensure responsible scaling across your organization
Clare Maher, Senior Manager of Product Marketing, Authenticx
Eric Prugh, Chief Product Officer, Authenticx
- Activate proven AI use cases to strengthen sales performance, optimize omnichannel engagement, and accelerate launch success.
- Apply AI to real commercial challenges through hands‑on exercises that build confidence and capability for day‑to‑day decision‑making
- Build a 90‑day action plan to scale AI responsibly with clear governance, practical steps, and quick-win opportunities
Terrel Marks, Life Sciences Transformation Leader, IBM
Inder Deep Singh, Patient Services Lead, IBM
Lauren Gurevitz, Lead Sales Engineer for Healthcare & Life Sciences, IBM
- Identify the critical stages of the patient journey from enrollment to adherence and define which journey-wide and stage-specific insights are most important to track to improve experience, accelerate time to therapy, and reduce friction.
- Explore where delays, breakdowns, and drop-off risk occur across access, affordability, and leading indicators that could enable earlier, more effective intervention.
- Which KPIs, behavioral signals, and outcome measures should be monitored to quantify intervention effectiveness, guide continuous improvement, and deliver measurable impact for patients and providers
Chris Savage, Managing Director, Propensity4, an Inizio Engage Company
Adam Booth, Analytics Director, Propensity4, an Inizio Engage Company
Sandhya Puliyampotta, Analytics Manager, Propensity4, an Inizio Engage Company
• Examine why nearly 80% of pharma AI initiatives stall at pilot stage due to fragmented, inconsistent, or hard to govern data.
• Explore how leading pharmaceutical organizations are building trusted, enterprise wide data foundations to enable high value use cases - from predictive patient identification and real world evidence to commercial effectiveness and precision medicine.
• Gain practical guidance on the five core data barriers, a step by step readiness framework that reduces manual prep by 60–80%, and how improved data accuracy, integration, security, and explainability drive 3–5x faster AI deployment and 30–40% gains in model performance across R&D, medical, and commercial teams.
Jerry Calvanese, Senior Director, Technical Sales – Industries, Informatica
• How pharma teams move from AI pilots and training into real, consistent daily use.
• Practical strategies for driving adoption through behaviors, workflows, and change management.
• A grounded, commercial-focused look at making AI stick—beyond tools, trends, and tech hype.
Alanna Peet, Managing Director, Senior Commercial Consulting Executive, Accenture
Patient Roundtable: Move beyond transactional engagement toward sustainable, measurable partnerships that align patient insights with enterprise priorities and long-term value creation
- Define authentic patient engagement and its relevance across pharma operations
- Connect patient engagement to measurable business outcomes and ROI
- Apply practical frameworks for partnering with patients and communities across the product lifecycle
- Learn from real-world case studies demonstrating enterprise-wide impact
Gladys Antelo-Allen, Associate Director of Education and Training, Field Building & Resources team, Camden Coalition
Evelyne Kane, MPH, Associate Director of Community Engagement & Capacity Building, Camden Coalition
Keith Berelowitz, Global Patient Advocate
Connie Montgomery, Global Patient Advocate & Retired OTR/L
Future-Ready Leadership: Empowering Women to Lead in the Age of AI and Data
• Justine Rochon, SVP, Head of R&D Data and Quantitative Sciences, Takeda
• Jacqueline Dioguardi, Global Pharma CIO, Roche, VP of Informatics, Genentech
• Amy Turnquist, VP, the Americas Operating Board, the Healthcare Businesswomen’s Association
Q. From your vantage point as an executive, how is AI reshaping what it means to lead in life sciences today?
Q, As AI accelerates change in how we work, what new leadership capabilities do you believe women must cultivate—both personally and within their teams—to stay future ready?
Q. If every woman in this room took one bold action tomorrow to prepare for the AI-driven future, what should it be?
- Why generative AI pilots stall in pharma, and how reliability and auditability become the key barriers to real world deployment.
- What “Glass Box Intelligence” looks like, including the Four Pillars: Decision Provenance, Architectural Auditability, Verifiable Logic, and the Forensic AI Trail.
- How peers are moving from pilots to production, with candid discussion, examples, and practical frameworks for building accurate, defensible, regulator ready AI.
Christopher Shipp, Founder, Humigent.ai
- Work hands‑on to translate a brand brief into real assets by blending AI acceleration with human-led interpretation and refinement.
- Harness AI to rapidly explore wide-ranging brand territories and push creative possibilities farther, faster.
- Spot where Human Inspiration adds tension, originality, and strategic judgment to elevate AI‑generated directions.
Joe J Daley, President, Addison Whitney
Adrienne Deaton, VP Creative Director, Addison Whitney
Emma Odum, AW, Creative Director, Addison Whitney
• Diagnose where their marketing orchestration breaks (process, governance, or ownership; not just tools)
• Identify structural blockers limiting content velocity or personalization
• Understand which AI use cases are operationally realistic in the next 6–12 months
• Leave with a framework to reduce cycle time or unlock compliant personalization
Qusai Mahesri, General Manager, Qualified Digital
Jake Wells, Chief Transformation Officer, Qualified Digital
*Please bring your laptop, this is a practical and interactive session
- Walk through real omnichannel journey maps anchored at congress – the booth interaction, the symposium Q&A, the KOL side conversation – and pinpoint exactly where the intelligence signal dies before it reaches your CRM, your rep, or your next campaign brief.
- Diagnose the gap together: using live examples from your own commercial models, the group pressure-tests congress identity resolution, data flow, and field activation to surface what is actually lost between the congress floor and commercial action.
- Co-create the fix in the room: leave with a peer-designed blueprint for turning congress into a live intelligence engine – resolving HCP signals to CRM records, triggering field follow-up, and feeding omnichannel orchestration in real time.
Pierre Metrailler, CEO, Onomi
